Novartis got another black eye in Asia this week as South Korea indicted a half-dozen executives on drug-rebate charges. But now the company may have a bigger…

Dynavax Technologies has a new FDA Adcomm date for consideration of its hepatitis B vaccine, Heplisav-B, after the agency earlier this year pushed back its…

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up,…

What with long summer days and vacations, it can be tough to keep up with required reading in July. To catch up with the best-read news, check out FiercePharma…

The Justice Department has drawn Celgene into its pharma-wide probe of financial ties with patient assistance programs, which help cover out-of-pocket drug…

Today is the first day for England’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICE faced…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…